Drug Profile
Octreotide oral - Enteris BioPharma
Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Enteris BioPharma
- Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuroendocrine tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Neuroendocrine-tumours in USA (PO, Tablet)
- 28 Jan 2020 Preclinical development is ongoing in USA (Enterisbiopharma pipeline, January 2020)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Neuroendocrine-tumours in USA (PO, Tablet)